Aster DM Healthcare (ASTERDM) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
18 Jun, 2026Market opportunity and industry trends
India's healthcare delivery market is projected to exceed $100 billion by FY26, driven by a vast population, low hospital bed density, and rising healthcare expenditure.
Out-of-pocket expenses remain high, but health insurance coverage is expected to expand to 46% by FY25.
Medical tourism and an aging population are significant growth drivers, with medical tourists projected to reach ~3 million by 2030.
Business overview and operational footprint
Operates 19 hospitals, 13 clinics, 215 pharmacies, and 232 labs/PECS across 15 cities in 5 states, with 4,867 capacity beds and 68% occupancy in FY24.
Holds the second-largest hospital network in South India, leading in Kerala and strong positions in Karnataka, Maharashtra, Andhra Pradesh, and Telangana.
Revenue mix is diversified across geographies and specialties, with 58% from niche specialties and increasing contributions from medical value travel and insurance.
Financial performance and growth
Revenue grew at a 23% CAGR over five years, reaching INR 3,699 crore in FY24; operating EBITDA margin expanded to 17%.
Adjusted PAT rose 63% YoY to INR 240 crore in FY24, with ROCE improving to 16.4%.
Mature hospitals delivered 22.4% EBITDA margin and 32% ROCE in FY24.
Net debt/EBITDA (pre-IndAS) improved to 1.1x.
Latest events from Aster DM Healthcare
- Aster DM and QCIL merge to form a top 3 Indian hospital chain with 10,150+ beds and strong growth.ASTERDM
Investor Presentation18 Jun 2026 - Merger forms a top-three Indian hospital chain with 10,150+ beds, strong synergies, and Blackstone backing.ASTERDM
M&A Announcement18 Jun 2026 - Merger with QCIL positions the group among India's top 3 hospital chains by scale and revenue.ASTERDM
Investor presentation3 Jun 2026 - Robust revenue and EBITDA growth, with the Quality Care merger and expansion fueling future gains.ASTERDM
Q4 25/261 May 2026 - 15% revenue and 22% EBITDA growth, merger progress, and major internal restructuring.ASTERDM
Q3 25/2610 Apr 2026 - FY25 profit surged on 12% revenue growth, margin gains, and QCIL merger, with strong dividends.ASTERDM
Q4 24/253 Feb 2026 - Q1 FY25 delivered 20% revenue growth, record profit, and expansion after GCC business sale.ASTERDM
Q1 24/252 Feb 2026 - Strong revenue, profit, and margin growth, boosted by GCC separation and cluster performance.ASTERDM
Q2 24/2519 Jan 2026 - Revenue and EBITDA surged, margins expanded, and a major merger and restructuring advanced.ASTERDM
Q3 24/259 Jan 2026